Dr. Chovatiya discusses a recent poster presented at the 2025 Revolutionizing Atopic Dermatitis Conference which evaluated the effectiveness of upadacitinib in achieving long-term maintenance of optimal skin and itch treatment targets in patients with atopic dermatitis. Patients who achieved at least 90 percent improvement in Eczema Area and Severity Index (EASI90) and/or minimal pruritus (Worst Pruritus Numerical Rating Scale score of 0 or 1) at Week 16 were monitored at Weeks 24, 52, 100, and 140 to assess if these scores could be maintained for an extended period of time. View the full poster here.
Reference:
-
Issa NT, Chovatiya R, Talia J, et al. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. Presented at: The Revolutionizing Atopic Dermatitis Conference; June 6, 2025, Nashville, Tennessee.